ARS Pharmaceuticals Inc (NASDAQ: SPRY) flaunted slowness of -0.73% at $14.88, as the Stock market unbolted on Wednesday, before settling in for the price of $14.99 at the close. Taking a more long-term approach, SPRY posted a 52-week range of $7.55-$18.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 59377.90%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -1764.10%. This publicly-traded company’s shares outstanding now amounts to $97.95 million, simultaneously with a float of $56.04 million. The organization now has a market capitalization sitting at $1.46 billion. At the time of writing, stock’s 50-day Moving Average stood at $12.13, while the 200-day Moving Average is $12.71.
ARS Pharmaceuticals Inc (SPRY) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the ARS Pharmaceuticals Inc industry. ARS Pharmaceuticals Inc’s current insider ownership accounts for 42.88%, in contrast to 50.11% institutional ownership. According to the most recent insider trade that took place on Apr 07 ’25, this organization’s Director sold 50,002 shares at the rate of 12.30, making the entire transaction reach 615,075 in total value, affecting insider ownership by 210,346.
ARS Pharmaceuticals Inc (SPRY) Earnings and Revenue Records
ARS Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -1764.10% and is forecasted to reach -0.55 in the upcoming year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Let’s observe the current performance indicators for ARS Pharmaceuticals Inc (SPRY). It’s Quick Ratio in the last reported quarter now stands at 14.04. The Stock has managed to achieve an average true range (ATR) of 0.98. Alongside those numbers, its PE Ratio stands at $194.00, and its Beta score is 0.76. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 16.38. Similarly, its price to free cash flow for trailing twelve months is now 112.48.
In the same vein, SPRY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.08, a figure that is expected to reach -0.34 in the next quarter, and analysts are predicting that it will be -0.55 at the market close of one year from today.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Now, what If we examine the latest scores posted by [ARS Pharmaceuticals Inc, SPRY]. During the last 5-days, its volume was lower the volume of 1.64 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 95.94% While, its Average True Range was 0.99.
Raw Stochastic average of ARS Pharmaceuticals Inc (SPRY) in the period of the previous 100 days is set at 94.03%, which indicates a major rise in contrast to 92.77% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 53.59% that was lower than 67.05% volatility it exhibited in the past 100-days period.
